Nanocarrier Drug Delivery Systems Research Articles

Applications of nanotechnology-mediated herbal nanosystems for ophthalmic drug.

In recent years, herbal nanomedicines have gained tremendous popularity for novel drug discovery. Nanotechnology has provided several advances in the healthcare sector, emerging several novel nanocarriers that potentiate the bioavailability and therapeutic efficacy of the herbal drug. The recent advances in nanotechnology with accelerated strategies of ophthalmic nanosystems have paved a new path for overcoming the limitations associated with ocular drug delivery systems, such as low bioavailability, poor absorption, stability, and precorneal drug loss. Ophthalmic drug delivery is challenging due to anatomical and physiological barriers. Due to the presence of these barriers, the herbal drug entry into the eyes can be affected when administered by following multiple routes, i.e., topical, injectables, or systemic. However, the advancement of nanotechnology with intelligent systems enables the herbal active constituent to successfully entrap within the system, which is usually difficult to reach employing conventional herbal formulations. Herbal-loaded nanocarrier drug delivery systems demonstrated enhanced herbal drug permeation and prolonged herbal drug delivery. In this current manuscript, an extensive search is conducted for original research papers using databases Viz., PubMed, Google Scholar, Science Direct, Web of Science, etc. Further painstaking efforts are made to compile and update the novel herbal nanocarriers such as liposomes, polymeric nanoparticles, solid lipid nanoparticles, nanostructure lipid carriers, micelles, niosomes, nanoemulsions, dendrimers, etc., which are mostly used for ophthalmic drug delivery system. This article presents a comprehensive survey of diverse applications used for the preventative measures and treatment therapy of varied eye disorders. Further, this article highlights the recent findings that the innovators are exclusively working on ophthalmic nanosystems for herbal drug delivery systems. The nanocarriers are promising drug delivery systems that enable an effective and supreme therapeutic potential circumventing the limitations associated with conventional ocular drug delivery systems. The nanotechnology-based approach is useful to encapsulate the herbal bioactive and prevent them from degradation and therefore providing them for controlled and sustained release with enhanced herbal drug permeation. Extensive research is still being carried out in the field of herbal nanotechnology to design an ophthalmic nanosystem with improved.

Theoretical investigations on modeling blood flow through vessel for understanding effectiveness of magnetic nanocarrier drug delivery systems

Theoretical investigations on modeling blood flow through vessel for understanding effectiveness of magnetic nanocarrier drug delivery systems

The Emerging Roles of Nanocarrier Drug Delivery System in Treatment of Intervertebral Disc Degeneration-Current Knowledge, Hot Spots, Challenges and Future Perspectives.

Low back pain (LBP) is a common condition that has substantial consequences on individuals and society, both socially and economically. The primary contributor to LBP is often identified as intervertebral disc degeneration (IVDD), which worsens and leads to significant spinal problems. The conventional treatment approach for IVDD involves physiotherapy, drug therapy for pain management, and, in severe cases, surgery. However, none of these treatments address the underlying cause of the condition, meaning that they cannot fundamentally reverse IVDD or restore the mechanical function of the spine. Nanotechnology and regenerative medicine have made significant advancements in the field of healthcare, particularly in the area of nanodrug delivery systems (NDDSs). These approaches have demonstrated significant potential in enhancing the efficacy of IVDD treatments by providing benefits such as high biocompatibility, biodegradability, precise drug delivery to targeted areas, prolonged drug release, and improved therapeutic results. The advancements in different NDDSs designed for delivering various genes, cells, proteins and therapeutic drugs have opened up new opportunities for effectively addressing IVDD. This comprehensive review provides a consolidated overview of the recent advancements in the use of NDDSs for the treatment of IVDD. It emphasizes the potential of these systems in overcoming the challenges associated with this condition. Meanwhile, the insights and ideas presented in this review aim to contribute to the advancement of precise IVDD treatment using NDDSs.

An Overview of Polymeric Nanoplatforms to Deliver Veterinary Antimicrobials.

There is an urgent need to find new solutions for the global dilemma of increasing antibiotic resistance in humans and animals. Modifying the performance of existing antibiotics using the nanocarrier drug delivery system (DDS) is a good option considering economic costs, labor costs, and time investment compared to the development of new antibiotics. Numerous studies on nanomedicine carriers that can be used for humans are available in the literature, but relatively few studies have been reported specifically for veterinary pharmaceutical products. Polymer-based nano-DDS are becoming a research hotspot in the pharmaceutical industry owing to their advantages, such as stability and modifiability. This review presents current research progress on polymer-based nanodelivery systems for veterinary antimicrobial drugs, focusing on the role of polymeric materials in enhancing drug performance. The use of polymer-based nanoformulations improves treatment compliance in livestock and companion animals, thereby reducing the workload of managers. Although promising advances have been made, many obstacles remain to be addressed before nanoformulations can be used in a clinical setting. Some crucial issues currently facing this field, including toxicity, quality control, and mass production, are discussed in this review. With the continuous optimization of nanotechnology, polymer-based DDS has shown its potential in reducing antibiotic resistance to veterinary medicines.

Nanoparticles for the Treatment of Bone Metastasis in Breast Cancer: Recent Advances and Challenges.

Although the frequency of bone metastases from breast cancer has increased, effective treatment is lacking, prompting the development of nanomedicine, which involves the use of nanotechnology for disease diagnosis and treatment. Nanocarrier drug delivery systems offer several advantages over traditional drug delivery methods, such as higher reliability and biological activity, improved penetration and retention, and precise targeting and delivery. Various nanoparticles that can selectively target tumor cells without causing harm to healthy cells or organs have been synthesized. Recent advances in nanotechnology have enabled the diagnosis and prevention of metastatic diseases as well as the ability to deliver complex molecular "cargo" particles to metastatic regions. Nanoparticles can modulate systemic biodistribution and enable the targeted accumulation of therapeutic agents. Several delivery strategies are used to treat bone metastases, including untargeted delivery, bone-targeted delivery, and cancer cell-targeted delivery. Combining targeted agents with nanoparticles enhances the selective delivery of payloads to breast cancer bone metastatic lesions, providing multiple delivery advantages for treatment. In this review, we describe recent advances in nanoparticle development for treating breast cancer bone metastases.

Targeting the Endocannabinoid System Present in the Glioblastoma Tumour Microenvironment as a Potential Anti-Cancer Strategy.

The highly aggressive and invasive glioblastoma (GBM) tumour is the most malignant lesion among adult-type diffuse gliomas, representing the most common primary brain tumour in the neuro-oncology practice of adults. With a poor overall prognosis and strong resistance to treatment, this nervous system tumour requires new innovative treatment. GBM is a polymorphic tumour consisting of an array of stromal cells and various malignant cells contributing to tumour initiation, progression, and treatment response. Cannabinoids possess anti-cancer potencies against glioma cell lines and in animal models. To improve existing treatment, cannabinoids as functionalised ligands on nanocarriers were investigated as potential anti-cancer agents. The GBM tumour microenvironment is a multifaceted system consisting of resident or recruited immune cells, extracellular matrix components, tissue-resident cells, and soluble factors. The immune microenvironment accounts for a substantial volume of GBM tumours. The barriers to the treatment of glioblastoma with cannabinoids, such as crossing the blood-brain barrier and psychoactive and off-target side effects, can be alleviated with the use of nanocarrier drug delivery systems and functionalised ligands for improved specificity and targeting of pharmacological receptors and anti-cancer signalling pathways. This review has shown the presence of endocannabinoid receptors in the tumour microenvironment, which can be used as a potential unique target for specific drug delivery. Existing cannabinoid agents, studied previously, show anti-cancer potencies via signalling pathways associated with the hallmarks of cancer. The results of the review can be used to provide guidance in the design of future drug therapy for glioblastoma tumours.

CARBON DOTS: Bioimaging and Anticancer Drug Delivery.

Cancer, responsible for approximately 10 million lives annually, urgently requires innovative treatments, as well as solutions to mitigate the limitations of traditional chemotherapy, such as long-term adverse side effects and multidrug resistance. This review focuses on Carbon Dots (CDs), an emergent class of nanoparticles (NPs) with remarkable physicochemical and biological properties, and their burgeoning applications in bioimaging and as nanocarriers in drug delivery systems for cancer treatment. The review initiates with an overview of NPs as nanocarriers, followed by an in-depth look into the biological barriers that could affect their distribution, from barriers to administration, to intracellular trafficking. It further explores CDs' synthesis, including both bottom-up and top-down approaches, and their notable biocompatibility, supported by a selection of in vitro, in vivo, and ex vivo studies. Special attention is given to CDs' role in bioimaging, highlighting their optical properties. The discussion extends to their emerging significance as drug carriers, particularly in the delivery of doxorubicin and other anticancer agents, underscoring recent advancements and challenges in this field. Finally, we showcase examples of other promising bioapplications of CDs, emergent owing to the NPs flexible design. As research on CDs evolves, we envisage key challenges, as well as the potential of CD-based systems in bioimaging and cancer therapy.

GELLAN GUM- AND PECTIN-MAGNETIC GRAPHENE OXIDE NANOCARRIERS LOADED WITH CINNAMALDEHYDE FOR MOSQUITO LARVAE CONTROL

Magnetic nanoparticles have evolved over the last few decades as nanocarriers in drug delivery systems for hydrophobic drugs. Here, novel gellan gum magnetic graphene oxide (GG-GO-Fe3O4) and pectin magnetic graphene oxide (PEC-GO-Fe3O4) nanocomposites were prepared to carry cinnamaldehyde to control Aedes aegypti larvae. Fourier transform infrared (FTIR) spectroscopy, field emission scanning electron microscopy (FESEM) and scanning transmission electron microscopy (STEM) were employed to investigate the physicochemical characteristics of the nanocomposites. Entrapment efficiencies and loading capacities of nanocomposites on cinnamaldehyde were examined using ultraviolet-visible analysis. The successful cinnamaldehyde loading was confirmed by C-C and C-O stretches in the FTIR spectra. Results of in vitro release study showed the capabilities of GG-GO-Fe3O4 as a drug carrier system, extending the cinnamaldehyde release period for 36 h, and the release profiles for both nanocomposites fit the Korsmeyer-Peppas kinetic model with correlation coefficient (R2) values of over 0.9809. The cinnamaldehyde-loaded GG-GO-Fe3O4 nanocomposites induced 68% mortality after 72 h of exposure, with LC50 values ranging from 2.0488 and 15.9121 mg/L. The conjugation of GO-Fe3O4 with biopolymers improved the water solubility of cinnamaldehyde by 36.41 to 62.83 times vs. free cinnamaldehyde in water (1.42 mg/mL). Overall, these results are beneficial for researchers dealing with mosquito control and prevention.

Uptake of surface-functionalized thermo-responsive polymeric nanocarriers in corticospinal tract motor neurons

Nanocarrier drug delivery systems are attractive options for targeted delivery of survival- and regeneration-enhancing therapeutics to neurons damaged by degenerative or traumatic central nervous system (CNS) lesions. Functional groups on nanocarrier surfaces allow derivatization with molecules to target specific cells but may affect cellular interactions and nanocarrier uptake. We synthesized differently sized –COOH and –NH2 surface functionalized polymeric nanocarriers (SFNCs) by emulsion copolymerization and assessed uptake by different cell types in mixed cortical cultures. Following 60-min incubation with SFNCs, mean intensity measurements of fluorescently labeled SFNCs indicated that corticospinal tract motor neurons (CSMNs) took up more COOH- or NH2- functionalized SFNCs with similar sizes (150 nm), compared to glia. However, larger diameter (750 nm) SFNCs were taken up at higher concentrations compared to smaller COOH-derivatized SFNCs (150 nm). These data suggest that larger SFNCs may provide an advantage for enhanced uptake by targeted neurons.

Photodynamic therapy using polymeric micelles containing photosensitizers

In recent years, photodynamic therapy (PDT) has emerged as a promising cancer treatment due to its minimal risk of harming normal cells and non-invasive nature, alleviating the burden on patients. PDT utilizes light and photosensitizers to exploit photochemical reactions for therapeutic purposes. However, a challenge arises post-PDT treatment, where residual photosensitizers in the body can induce phototoxicity upon exposure to sunlight.To address this issue, the concept of drug delivery systems (DDS) has garnered attention. DDS aims to control drug distribution in the body, maximizing therapeutic effects while minimizing side effects. In this study, we explore the use of polymeric micelles as nanocarriers for DDS, leveraging their advantages such as tumor-specific accumulation and low toxicity.The synthesis of photosensitizer-containing block copolymers was conducted, followed by evaluation of micellization using NMR and assessment of phototoxicity utilizing HeLa cells. The obtained results revealed a critical micelle concentration (CMC) of 0.16 mg/mL. Notably, significant cell toxicity was observed at the CMC concentration in the phototoxicity assay, highlighting the potential of these polymeric micelles as an effective nanocarrier system for enhanced photodynamic therapy.

ROS-responsive polymeric micelles with aggregation-induced emission effects for drug delivery and cellular imaging

The ROS-responsive amphiphilic copolymer micelles mPEG-TK-PCL-TPE, combined with AIE properties, enable real-time drug release monitoring and intracellular tracing, and ensures stable circulation and rapid release in tumors.

Different Approaches for Transdermal Nano-Carrier Delivery System

Transdermal drug delivery is a validated technology that makes a significant contribution to global pharmaceutical care. Since 1980, the sector has seen impressive growth with several commercial successes. The term transdermal drug delivery refers to the delivery of a drug across the layers of skin with the intention of allowing the drug to be absorbed through the skin in a predetermined and controlled rate manner. Skin is one of the largest organs that act as an efficient barrier for drug delivery. The present study focuses on the different approaches of nano-carrier system that delivers the nano-carrier drug across the skin barrier with the help of transdermal delivery system. Nano-carrier drug delivery systems are one of the biggest challenges to deliver drug into systemic circulation by crossing the skin barrier providing a passive drug delivery strategy that is known to be safer and faster than the conventional method. In this review, we describe the diverse types of nano-carriers approaches that have been synthesized for transdermal delivery system includes liposomes, niosomes, ethosomes, solid lipid nanoparticles (SLN), nanostructured lipid carrier (NLC), polymeric nanoparticles, nanocrystals, nanofibers and nanosuspension/nanoemulsion. Several characterization methods of transdermal delivery system have been proposed to control the behavior of nano-carriers, along with in-vitro and in-vivo and other evaluation parameters. It was concluded that the compatibility of nano-carriers with the skin structure should be considered for transdermal nanocarrier delivery systems, which will be the most preferred route for drug delivery in the future as it offers high patient compliance, controlled dosing, low frequency of dosing, high physico-chemical stability and better dermal bioavailability, etc.

Prospects of plant-derived exosome-like nanocarriers in oncology and tissue engineering.

Almost all cell types, either in vivo or in vitro, create extracellular vesicles (EVs). Among them are exosomes (EXOs), i.e., tiny nanovesicles containing a lipid bilayer, proteins, and RNAs that are actively involved in cellular communication, indicating that they may be exploited as both diagnostics and therapeutics for conditions like cancer. These nanoparticles can also be used as nanocarriers in many types of research to carry agents such as drugs. Plant-derived exosome-like nanoparticles (PENs) are currently under investigation as a substitute for EXOs formed from mammalian cells, allowing researchers to get beyond the technical constraints of mammalian vesicles. Because of their physiological, chemical, and biological properties, PENs have a lot of promise for use as nanocarriers in drug delivery systems that can deliver various dosages, especially when it comes to large-scale repeatability. The present study has looked at the origins and isolation techniques of PENs, their anticancer properties, their usage as nanocarriers in the treatment of different illnesses, and their antioxidant properties. These nanoparticles can aid in the achievement of therapeutic objectives, as they have benign, non-immunogenic side effects and can pass biological barriers. Time-consuming and perhaps damaging PEN separation techniques is used. For the current PEN separation techniques to be used in commercial and therapeutic settings, they must be altered. In this regard, the concurrent application of biological sciences can be beneficial for improving PEN separation techniques. PENs' innate metabolic properties provide them a great deal of promise for application in drug delivery systems. However, there could be a risk to both the loaded medications and the intrinsic bioactive components if these particles are heavily armed with drugs. Therefore, to prevent these side effects, more studies are needed to devise sophisticated drug-loading procedures and to learn more about the physiology of PENs.

Nanocarrier‐Based Drug Delivery Systems using Microfluidic‐Assisted Techniques

Nanocarrier‐mediated drug delivery in life science and patient care is now highly recognized and has gained significant traction in pharmaceuticals for clinical applications. Besides, the incorporation of microfluidic technology for the synthesizing and delivery of nanocarriers facilitates preclinical drug testing under biomimicking physiological conditions, which further increases the prospect of nanocarrier drug delivery systems in clinical use. Indeed, an inherent amenability of microfluidics shows fine‐tuned manipulation and controlled release of nanocarrier drugs in a spatiotemporal manner. The progress of microfluidic‐assisted potential drug delivery platforms is reviewed and summarized with a focus on factors determining the design of novel nanodrug delivery microfluidic systems, on‐chip functionalization and synthesis mechanisms of nanodrugs, and stimulation‐responsive and organ‐specific drug delivery platforms, including different challenges associated with developing platforms in benchtop research that hinder platforms’ clinical translation. Moreover, the commercial scenario and prospects of the microfluidic nanodrug delivery platforms are evaluated, and further predictive suggestions are provided for developing multitargeting microfluidic/organ‐on‐a‐chip nanodrug delivery platforms and overcoming the challenges associated with commercialization. This review recognizes that although numerous reports have reinforced the promise of microfluidic nanodrug delivery platforms, much remains to be done in lab and benchtop works to realize it in clinical practice through commercialization.

Active Transport and Ocular Distribution of Intravitreally Injected Liposomes.

Drug delivery to the retina remains a challenge due to ocular barriers and fast clearing mechanisms. Nanocarrier drug delivery systems (NDDSs) hold the promise of prolonging intraocular retention times and increasing drug concentrations in the retina. Anionic and cationic PEGylated liposomes, loaded with oxaliplatin (OxPt) to be used as trace element, were prepared from dry lipid powders. The differently charged liposomes were intravitreally injected in C57BL/6JrJ mice; eyes were harvested 2hours and 24hours post-injection. To investigate active transport mechanisms in the eye, a subset of mice were pre-injected with chloroquine before injection with cationic liposomes. Eyes were dissected and the distribution of OxPt in different tissues were quantified by inductively coupled plasma mass spectrometry (ICP-MS). Both liposome formulations enhanced the retention time of OxPt in the vitreous over free OxPt. Surprisingly, when formulated in cationic liposomes, OxPt translocated through the retina and accumulated in the RPE-sclera. Pre-injection with chloroquine inhibited the transport of liposomal OxPt from the vitreous to the RPE-sclera. We show that liposomes can enhance the retention time of small molecular drugs in the vitreous and that active transport mechanisms are involved in the trans retinal transport of NDDS after intravitreal injections. These results highlight the need for understanding the dynamics of ocular transport mechanisms in living eyes when designing NDDS with the back of the eye as the target. Active transport of nanocarriers through the retina will limit the drug concentration in the neuronal retina but might be exploited for targeting the RPE.

New cage-based imine and ester linked COF as a smart nanocarrier drug delivery system

New cage-based imine and ester linked COF as a smart nanocarrier drug delivery system

PEGylated bottom-up synthesized graphene nanoribbons loaded with camptothecin as potential drug carriers

This work discusses the potential use of bottom-up synthesized graphene nanoribbons (GNRs) as nano-carriers for drug delivery systems (DDSs). GNRs have a high loading capacity for anticancer drugs due to their high specific surface area and non-covalent adsorption with hydrophobic anticancer drug molecules. Herein, we synthesized GNRs using a bottom-up approach, modified with PEG2000 (GNR-PEG) and PEG2000 carrying folic acid chains (GNR-PEG-FA), and then loaded with camptothecin (CPT). The targeting ability mediated by folic acid of the GNR derivative was evaluated using cellular assays, and the cytotoxicity of GNR systems loaded with CPT was assessed by in vitro studies. They suggest that the functionalization of GNR derivatives with folic acid significantly affects their interaction with cells expressing different levels of folic acid receptors. The authors also explore the possibility to employ GNRs in photothermal therapy (PTT). GNR-PEG and GNR-PEG-FA display minor or no toxicity in standard cell cultures, but they show remarkable thermal response upon NIR irradiation, causing complete loss of cell viability within a few hours of treatment. This work highlights the potential of GNRs as DDSs and emphasizes the importance of further research on their biocompatibility and as a platform for PTT.

Rational Design and Multicomponent Synthesis of Lipid-Peptoid Nanocomposites towards a Customized Drug Delivery System Assembly.

Nanotechnology has assumed a significant role over the last decade in the development of various technologies applied to health sciences. This becomes even more evident with its application in controlled drug delivery systems. In this context, peptoids are a promising class of compounds for application as nanocarriers in drug delivery systems. These compounds can be obtained efficiently and with highly functionalized structural diversity via the Ugi 4-component reaction (U-4CR). Herein, we report the design of the process control strategy for the future development of lipid-peptoid-based customized drug delivery system assemblies. Over 20 lipid-peptoid nanocomposites were synthesized via the U-4CR in good to excellent yields. These products were successfully submitted to the nanoparticle formation by the emulsification-evaporation process from lipophilic solution and analyzed via Dynamic Light Scattering (DLS). Several molecules generated nanoparticles with a size ≤200 nm, making them good candidates for drug delivery systems, such as in cancer treatment.

Carbon quantum dots-based fluorescent layered double hydroxide for targeted drug delivery application

Layered double hydroxides (LDHs) are a class of layered materials that have received great attention as drug delivery carriers due to their excellent properties such as biocompatibility, chemical stability, easy synthesis, anion exchange capacity, and controlled drug release. In this research, LDH nanosheets based on Ca and Al were synthesized by a coprecipitation method. The LDH nanosheets were in situ coated by polyethylene glycol (PEG). The LDH nanosheets were decorated with carbon quantum dots (CQDs) derived from citric acid by a hydrothermal method and targeted with folic acid. Doxorubicin hydrochloride (DOX) was used as a model drug to investigate the drug loading and release of the fluorescent LDH. XRD analysis showed that the content of PEG in the synthesis medium affects the crystallinity of the LDHs. FTIR analysis confirmed the successful attachment of CQDs and folic acid (FA) on LDH nanosheets. The fluorescence of the synthesized nanohybrid was influenced by the CQDs content. UV–Vis spectroscopy showed the DOX can be loaded on the nanohybrid with a loading efficiency of 32 %. The drug release of the nanohybrid is pH-dependent. The drug can be released up to 83 % within 12 h in the acidic environment while the release reaches 63 % in the physiological pH at the same time. The synthesized CQDs can be used as pH-dependent fluorescent and targeted nanocarriers in drug delivery systems.

Responsive nanosystems for targeted therapy of ulcerative colitis: Current practices and future perspectives

The pharmacological approach to treating gastrointestinal diseases is suffering from various challenges. Among such gastrointestinal diseases, ulcerative colitis manifests inflammation at the colon site specifically. Patients suffering from ulcerative colitis notably exhibit thin mucus layers that offer increased permeability for the attacking pathogens. In the majority of ulcerative colitis patients, the conventional treatment options fail in controlling the symptoms of the disease leading to distressing effects on the quality of life. Such a scenario is due to the failure of conventional therapies to target the loaded moiety into specific diseased sites in the colon. Targeted carriers are needed to address this issue and enhance the drug effects. Conventional nanocarriers are mostly readily cleared and have nonspecific targeting. To accumulate the desired concentration of the therapeutic candidates at the inflamed area of the colon, smart nanomaterials with responsive nature have been explored recently that include pH responsive, reactive oxygen species responsive (ROS), enzyme responsive and thermo – responsive smart nanocarrier systems. The formulation of such responsive smart nanocarriers from nanotechnology scaffolds has resulted in the selective release of therapeutic drugs, avoiding systemic absorption and limiting the undesired delivery of targeting drugs into healthy tissues. Recent advancements in the field of responsive nanocarrier systems have resulted in the fabrication of multi-responsive systems i.e. dual responsive nanocarriers and derivitization that has increased the biological tissues and smart nanocarrier’s interaction. In addition, it has also led to efficient targeting and significant cellular uptake of the therapeutic moieties. Herein, we have highlighted the latest status of the responsive nanocarrier drug delivery system, its applications for on–demand delivery of drug candidates for ulcerative colitis, and the prospects are underpinned.